Grimmer T, Drzezga A, Kurz A
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Zentrum für kognitive Störungen, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, 81675, München, Deutschland.
Nervenarzt. 2010 May;81(5):602-6. doi: 10.1007/s00115-010-2951-6.
Imaging techniques for in vivo visualization of cerebral amyloid using positron emission tomography (PET) have been tested in clinical trails over the past 5 years. Based on a selected overview of the literature including our own studies the various radiopharmaceuticals are presented and the current status of research on the validity of amyloid PET imaging as well as its suitability for early and differential diagnosis of Alzheimer's disease (AD) are described. The findings available up to now support the validity of amyloid PET imaging and suggest a possible benefit in differential diagnosis. However, there are as yet no studies with large sample sizes. The possible use for the early diagnosis of AD should be viewed critically, particularly due to the lack of treatment options.
在过去5年中,正电子发射断层扫描(PET)用于脑淀粉样蛋白活体可视化的成像技术已在临床试验中进行了测试。基于包括我们自己研究在内的文献精选综述,介绍了各种放射性药物,并描述了淀粉样蛋白PET成像有效性及其对阿尔茨海默病(AD)早期和鉴别诊断适用性的研究现状。目前可得的研究结果支持淀粉样蛋白PET成像的有效性,并表明其在鉴别诊断中可能具有益处。然而,目前尚无大样本量的研究。对于AD早期诊断的可能用途应持谨慎态度,特别是由于缺乏治疗选择。